Eam Investors, LLC Cyma Bay Therapeutics, Inc. Transaction History

Eam Investors, LLC

$581 Million
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.63 - $24.47 $2.2 Million - $4.27 Million	-174,412 Reduced 45.71%	207,152 $4.89 Million
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $97,088 - $157,522	8,940 Added 2.4%	381,564 $5.69 Million
Q2 2023 Aug 11, 2023	BUY	$7.47 - $10.95 $418,544 - $613,528	56,030 Added 17.7%	372,624 $4.08 Million
Q1 2023 Jul 12, 2023	BUY	$5.88 - $9.59 $1.53 Million - $2.49 Million	259,691 Added 456.37%	316,594 $2.76 Million
Q1 2023 May 12, 2023	SELL	$5.88 - $9.59 $2.9 Million - $4.73 Million	-493,567 Reduced 89.66%	56,903 $496,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $678,428 - $1.32 Million	210,692 Added 62.01%	550,470 $3.45 Million
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $941,185 - $1.44 Million	339,778 New	339,778 $1.19 Million
Q4 2020 Feb 11, 2021	SELL	$5.73 - $9.03 $2.03 Million - $3.2 Million	-354,337 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$3.32 - $7.24 $1.18 Million - $2.57 Million	354,337 New	354,337 $2.57 Million
Q3 2018 Nov 08, 2018	SELL	$10.88 - $14.52 $1.05 Million - $1.4 Million	-96,188 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$10.66 - $14.38 $2.53 Million - $3.42 Million	-237,549 Reduced 71.18%	96,188 $1.29 Million
Q1 2018 May 14, 2018	SELL	$9.0 - $15.16 $900,684 - $1.52 Million	-100,076 Reduced 23.07%	333,737 $4.34 Million
Q4 2017 May 21, 2018	SELL	$7.67 - $9.31 $843,715 - $1.02 Million	-110,002 Reduced 20.23%	433,813 $3.99 Million
Q4 2017 Feb 12, 2018	SELL	$7.67 - $9.31 $384,949 - $467,259	-50,189 Reduced 8.45%	543,815 $5 Million
Q3 2017 Nov 08, 2017	BUY	$5.95 - $8.26 $3.53 Million - $4.91 Million	594,004	594,004 $4.79 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Account